Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1

Mona Rigaud, Henry Pollack, Eugene Leibovitz, Kimi Kim, Deborah Persaud, Aditya Kaul, Robert Lawrence, David Di John, William Borkowsky, Keith Krasinski

Research output: Contribution to journalArticle

Abstract

To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92% for the children who recelved prophylaxis and 74% for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.

Original languageEnglish (US)
Pages (from-to)476-480
Number of pages5
JournalJournal of Pediatrics
Volume125
Issue number3
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Pneumocystis Pneumonia
Chemoprevention
HIV-1
Virus Diseases
Sulfamethoxazole Drug Combination Trimethoprim
CD4 Lymphocyte Count
T-Lymphocytes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. / Rigaud, Mona; Pollack, Henry; Leibovitz, Eugene; Kim, Kimi; Persaud, Deborah; Kaul, Aditya; Lawrence, Robert; John, David Di; Borkowsky, William; Krasinski, Keith.

In: Journal of Pediatrics, Vol. 125, No. 3, 1994, p. 476-480.

Research output: Contribution to journalArticle

Rigaud, Mona ; Pollack, Henry ; Leibovitz, Eugene ; Kim, Kimi ; Persaud, Deborah ; Kaul, Aditya ; Lawrence, Robert ; John, David Di ; Borkowsky, William ; Krasinski, Keith. / Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. In: Journal of Pediatrics. 1994 ; Vol. 125, No. 3. pp. 476-480.
@article{15eb35d018d349f6811f2412c321c9e6,
title = "Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1",
abstract = "To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92{\%} for the children who recelved prophylaxis and 74{\%} for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.",
author = "Mona Rigaud and Henry Pollack and Eugene Leibovitz and Kimi Kim and Deborah Persaud and Aditya Kaul and Robert Lawrence and John, {David Di} and William Borkowsky and Keith Krasinski",
year = "1994",
doi = "10.1016/S0022-3476(05)83301-3",
language = "English (US)",
volume = "125",
pages = "476--480",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1

AU - Rigaud, Mona

AU - Pollack, Henry

AU - Leibovitz, Eugene

AU - Kim, Kimi

AU - Persaud, Deborah

AU - Kaul, Aditya

AU - Lawrence, Robert

AU - John, David Di

AU - Borkowsky, William

AU - Krasinski, Keith

PY - 1994

Y1 - 1994

N2 - To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92% for the children who recelved prophylaxis and 74% for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.

AB - To evaluate the efficacy of primary chemoprophylaxis in preventing Pneumocystis carinii pneumonia (PCP) in infants with perinatal human immunodeficiency virus-1 infection during the first year of life, we conducted a retrospective chart review of infants with human immunodeficiency virus-1 infection born at New York University Medical Center-Bellevue Hospital Center, in New York. Between March 1989 and March 1993, 24 infants received primary chemoprophylaxis with trimethoprim-sulfamethoxazole in the first year of life and 24 infants did not receive primary prophylaxis. The CD4+ T-lymphocyte counts in the two groups did not differ during the first year of life. The median age at the time of initiation of prophylaxis was 3 months, and the average duration of prophylaxis was 5.5 months. Among the infants who had not recelved prophylaxis, five cases of PCP were diagnosed at a median age of 5 months; in contrast, no cases of PCP were observed in the infants receiving prophylaxis (log-rank test, p=0.017). The probability of surviving after 1 year of age was 92% for the children who recelved prophylaxis and 74% for those who did not (long-rank test, p=0.035). These data indicate that chemoprophylaxis is highly effective in preventing primary PCP and improving survival time in infants with human immunodeficiency virus-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=0027989439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027989439&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(05)83301-3

DO - 10.1016/S0022-3476(05)83301-3

M3 - Article

VL - 125

SP - 476

EP - 480

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 3

ER -